Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019		Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 17,406,608		$ 103,695
Prepaid expenses and other	726,959		156,628
Total current assets	18,133,567		260,323
Property and equipment, net	26,929		29,508
Intangible assets, net	1,223,000		41,692
Other assets	0		12,800
Total assets	19,383,496		344,323
Current liabilities:
Accounts payable	1,488,961		1,412,951
Accrued expenses	1,296,606		601,889
Restructuring reserve	858,332	[1]	0
Total current liabilities	3,643,899		2,014,840
Noncurrent liability:
Deferred tax liability	157,000		0
Convertible promissory notes payable	0		30,000
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, 5,000,000 shares authorized at September 30, 2019 and December 31, 2018, 0 outstanding	0		0
Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2019 and December 31, 2018, 5,278,850 shares and 3,417,187 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	1,742		1,128
Additional paid-in capital	39,414,792		19,311,529
Accumulated deficit	(23,833,937)		(21,013,174)
Total stockholders' equity (deficit)	15,582,597		(1,700,517)
Total liabilities and stockholders' equity (deficit)	$ 19,383,496		$ 344,323

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. The severance costs continue through September 2020. For the nine months ended September 30, 2019, the Company paid $1,211,939 of restructuring expense which was previously recorded on Edge Therapeutics financials.